DTL
SLN icon

Dynamic Technology Lab’s Silence Therapeutics SLN Stock Holding History

Dynamic Technology Lab’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,490
Closed -$55.3K – 1049
2026
Q1 		$55.3K Buy
+10,490
New +$57.8K 0.01% 813

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dynamic Technology Lab's SLN Position: Q2 2026 in Review

Dynamic Technology Lab sold out of Silence Therapeutics (SLN) in Q2 2026, closing a stake of 10,490 shares — an estimated $55.3K sold.

Dynamic Technology Lab first reported a position in SLN in Q1 2026 and held it in 1 quarter. The position peaked at $55.3K in Q1 2026. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Dynamic Technology Lab reported no remaining Silence Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dynamic Technology Lab sold 10,490 Silence Therapeutics shares in Q2 2026, an estimated $55.3K.
  • Dynamic Technology Lab first reported a position in Silence Therapeutics in Q1 2026 and held it in 1 quarter.
  • Dynamic Technology Lab's Silence Therapeutics position peaked at $55.3K in Q1 2026.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Dynamic Technology Lab's 13F filing for Q2 2026, filed 13 Aug 2026.